CompletedNCT00566449
Safety study of JNJ-31001074 in ADHD
Researchers compared JNJ-31001074 and placebo, tracking side effects to assess safety in adults with ADHD.
Medication studyAges 18–64United States
Understand this study
What did researchers investigate?
Researchers compared JNJ-31001074 and placebo, tracking side effects to assess safety in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Irvine and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateDecember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 32
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT00566449
- Official title
Show the full official title
A Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Investigate the Safety and Efficacy of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder
Recruitment & locations
CompletedIrvine · Lafayette · San Francisco
18 more locations
- Bradenton
- Fort Myers
- Orlando
- South Miami
- Eagle
- Libertyville
- Overland Park
- Boston
- Farmington
- Chapel Hll
- Raleigh
- Dayton
- Portland
- Media
- Austin
- Houston
- Herndon
- Seattle
Questions about this study
What did researchers investigate?
Researchers compared JNJ-31001074 and placebo, tracking side effects to assess safety in adults with ADHD.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo and JNJ-31001074.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)